XML 45 R25.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Revenue | 12 Months Ended
--- | ---
Dec. 31, 2021
Revenue from Contract with Customer [Abstract] |
Revenue from Contract with Customer [Text Block] | NOTE P – REVENUE We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes in our consolidated statements of operations. The following tables disaggregate our revenue from contracts with customers by business and geographic region (in millions):
| Year Ended December 31,
| 2021 |  | 2020 |  | 2019
Businesses | U.S. |  | OUS |  | Total |  | U.S. |  | OUS |  | Total |  | U.S. |  | OUS |  | Total
Endoscopy | $ | 1,222 |  |  | $ | 919 |  |  | $ | 2,141 |  |  | $ | 1,000 |  |  | $ | 780 |  |  | $ | 1,780 |  |  | $ | 1,080 |  |  | $ | 814 |  |  | $ | 1,894 |
Urology and Pelvic Health | 1,120 |  |  | 463 |  |  | 1,583 |  |  | 918 |  |  | 368 |  |  | 1,286 |  |  | 1,005 |  |  | 408 |  |  | 1,413 |
Cardiac Rhythm Management | 1,214 |  |  | 805 |  |  | 2,019 |  |  | 992 |  |  | 712 |  |  | 1,704 |  |  | 1,135 |  |  | 804 |  |  | 1,939 |
Electrophysiology | 128 |  |  | 237 |  |  | 365 |  |  | 118 |  |  | 169 |  |  | 287 |  |  | 148 |  |  | 180 |  |  | 329 |
Neuromodulation | 713 |  |  | 196 |  |  | 909 |  |  | 610 |  |  | 151 |  |  | 761 |  |  | 695 |  |  | 178 |  |  | 873 |
Interventional Cardiology | 1,508 |  |  | 1,530 |  |  | 3,038 |  |  | 981 |  |  | 1,317 |  |  | 2,299 |  |  | 1,293 |  |  | 1,522 |  |  | 2,816 |
Peripheral Interventions | 996 |  |  | 824 |  |  | 1,820 |  |  | 888 |  |  | 689 |  |  | 1,577 |  |  | 741 |  |  | 651 |  |  | 1,392 |
Specialty Pharmaceuticals | 10 |  |  | 4 |  |  | 13 |  |  | 193 |  |  | 27 |  |  | 219 |  |  | 70 |  |  | 11 |  |  | 81 |
Net Sales | $ | 6,911 |  |  | $ | 4,978 |  |  | $ | 11,888 |  |  | $ | 5,701 |  |  | $ | 4,212 |  |  | $ | 9,913 |  |  | $ | 6,167 |  |  | $ | 4,569 |  |  | $ | 10,735 |
On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Our consolidated net sales and income (loss) before income taxes include Specialty Pharmaceuticals up to the date of the closing of the transaction.
| Year Ended December 31,
Geographic Regions | 2021 |  | 2020 |  | 2019
U.S. | $ | 6,901 |  |  | $ | 5,508 |  |  | $ | 6,097 |
EMEA (Europe, Middle East and Africa) | 2,518 |  |  | 2,097 |  |  | 2,264 |
APAC (Asia-Pacific) | 2,070 |  |  | 1,781 |  |  | 1,898 |
LACA (Latin America and Canada) | 386 |  |  | 307 |  |  | 395 |
Medical Devices | 11,875 |  |  | 9,694 |  |  | 10,654 |
U.S. | 10 |  |  | 193 |  |  | 70 |
International | 4 |  |  | 27 |  |  | 11 |
Specialty Pharmaceuticals | 13 |  |  | 219 |  |  | 81 |
Net Sales | $ | 11,888 |  |  | $ | 9,913 |  |  | $ | 10,735 |
Emerging Markets(1) | $ | 1,429 |  |  | $ | 1,138 |  |  | $ | 1,282 |
(1) We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2021, modified our list to include the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, Turkey and Vietnam. We have revised prior period amounts to conform to the current year's presentation. Contract liabilities are classified within Other current liabilities and Other long-term liabilities in our accompanying consolidated balance sheets. Our deferred revenue balance was $484 million as of December 31, 2021 and $395 million as of December 31, 2020. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System within our Cardiac Rhythm Management (CRM) business, for which revenue is recognized over the average service period based on device and patient longevity. Our contractual liabilities also include deferred revenue related to the LUX-Dx™ Insertable Cardiac Monitor (ICM) system, also within our CRM business, for which revenue is recognized over the average service period based on device longevity and usage. We recognized revenue of $159 million in 2021 that was included in the above contract liability balance as of December 31, 2020. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred. We capitalize sales force commissions related to contracts with customers when the associated revenue is expected to be earned over a period that exceeds one year. Deferred commissions are primarily related to the sale of devices enabled with our LATITUDE™ Patient Management System. We have elected to expense commission costs when incurred for contracts with an expected duration of one year or less. Capitalized commission fees are amortized over the period the associated products or services are transferred. Similarly, we capitalize certain recoverable costs related to the delivery of the LATITUDE™ Remote Monitoring Service. These fulfillment costs are amortized over the average service period. We received FDA approval in mid-2020 and began the U.S. launch of our next generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device within our Interventional Cardiology business. The next generation WATCHMAN FLX™ Device is indicated to reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) who need an alternative to oral anticoagulation therapy by permanently closing off the left atrial appendage. In 2020, we recorded $179 million in revenue reserves primarily related to our conversion to a consignment commercial model for our LAAC franchise with the launch of our next-generation WATCHMAN FLX™ Device in the U.S. In connection with the conversion, we repurchased customer-owned inventory and will recognize revenue for consigned units as they are consumed by customers. Refer to Note A – Significant Accounting Policies for additional information on our accounting policies relating to revenue recognition.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -URI http://asc.fasb.org/topic&trid=49130388 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b)(2) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration